ANCA-Associated Vasculitis

Comorbidities Seen with ANCA-Associated Vasculitis

The damaging potential of many inflammatory disorders is magnified by well-known associated comorbid conditions. This is particularly true in lupus, rheumatoid…

 MI Risk Nearly Doubled in GPA

Risk is highest shortly after diagnosis

Remission more likely with rituximab than with cyclophosphamide

Rituximab is increasingly the go-to drug in severe and refractory ANCA-Associated Vasculitis (AAV), both for remission induction as well as for remission maintenance.

Challenges and Opportunities in the Management of ANCA-Associated Vasculitis

The goal of this activity is to facilitate appropriate treatment and monitoring choices for patients with ANCA-associated vasculitis, including the appropriate roles of various standard and new induction and maintenance therapies.

Emerging treatments presented for relapsing vasculitis

Emerging treatments presented for relapsing vasculitis:
Nucala (Mepolizumab), an anti-IL5 from GSK, is FDA-approved for the treatment of severe eosinophilic asthma. It is being studied for treating EGPA (Eosinophilic Granulomatous Polyangiitis, formally known as Churg-Strauss Syndrome).